RxNorm 2044714
amantadine 129 MG 24HR Extended Release Oral Tablet
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 2044714 unique identifier include: amantadine 129 MG 24HR Extended Release Oral Tablet (10270620), amantadine 129 MG (as amantadine HCl 160 MG) 24 HR Extended Release Oral Tablet (10270619) and 24 HR amantadine 129 MG Extended Release Oral Tablet (12346700).
RxNorm Atom ID: 10270620 - Prescribable Name
amantadine 129 MG 24HR Extended Release Oral Tablet
- RXCUI:
- 2044714 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 10270620 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- amantadine 129 MG 24HR Extended Release Oral Tablet - Description of concept identifier
- Term Type (TTY):
- PSN - Term type in source with name and description
- Term Type Name:
- Prescribable Name - Name of term type in source
- Term Type Description:
- Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept. - Description of term type in source
- Code:
- 2044714 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom ID: 10270619 - Synonym
amantadine 129 MG (as amantadine HCl 160 MG) 24 HR Extended Release Oral Tablet
- RXCUI:
- 2044714 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 10270619 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- amantadine 129 MG (as amantadine HCl 160 MG) 24 HR Extended Release Oral Tablet - Description of concept identifier
- Term Type (TTY):
- SY - Term type in source with name and description
- Term Type Name:
- Synonym - Name of term type in source
- Term Type Description:
- Synonym of another TTY, given for clarity. - Description of term type in source
- Code:
- 2044714 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom ID: 12346700 - Semantic Clinical Drug
24 HR amantadine 129 MG Extended Release Oral Tablet
- RXCUI:
- 2044714 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12346700 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- 24 HR amantadine 129 MG Extended Release Oral Tablet - Description of concept identifier
- Term Type (TTY):
- SCD - Term type in source with name and description
- Term Type Name:
- Semantic Clinical Drug - Name of term type in source
- Term Type Description:
- Ingredient + Strength + Dose Form - Description of term type in source
- Code:
- 2044714 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240401F - The source version
- Source Date:
- March 04, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
RxNorm Atom 12346700 Attributes
| Property | Value | Explanation |
|---|---|---|
| RXN AI | {2044712} 282415 | RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value |
| RXN AM | {2044712} 620 | RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value |
| RXN AVAILABLE STRENGTH | 129 MG | Available drug strengths listed in the order of ingredients from the drug |
| RXN BOSS FROM | {2044712} AM | Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value |
| RXN HUMAN DRUG | US | Drug available for use in Humans |
| RXN QUANTITY | 24 HR | Normal Form quantity factor |
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Amantadine
Amantadine is used to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) and other similar conditions. It is also used to control movement problems that are a side effect of certain medications used to treat Parkinson's disease. Amantadine extended-release capsules (Gocovri) are used along with the combination of levodopa and carbidopa (Rytary, Sinemet) to treat ''off'' episodes (times of difficulty moving, walking, and speaking that may happen when other medications wear off) in people with Parkinson's disease. It also is used to prevent symptoms of influenza A virus infection and for treatment of respiratory infections caused by influenza A virus. Amantadine is in a class of medications called adamantanes. It is thought to work to control movement problems by increasing the amount of dopamine in certain parts of the body. It works against influenza A virus by stopping the spread of the virus in the body.
[Learn More]
* Please review the disclaimer below.